Ipilimumab first demonstrated clinical efficacy in melanoma during a trial in which patients with metastatic melanoma were treated with ipilimumab (3 mg/kg) with or without a gp100 vaccine compared to the gp100 vaccine alone. The gene discussed is PMEL; the disease is melanoma.